BOSTON, April 4, 2016 /PRNewswire/ --
For non-US medical media only.
For journalistic assessment and preparation before publication.
Oral Presentation# OR36-1
Today, new data from the three-year part of the phase 3a SCALE(TM) (Satiety and Clinical Adiposity - Liraglutide Evidence) Obesity and Prediabetes trial were presented at the Endocrine Society's 98th Annual Meeting and Expo (ENDO 2016). The three-year part of the trial (n=2,254 adults with obesity or who were overweight with comorbidities and had prediabetes at baseline), data demonstrated that 160 weeks of treatment with Saxenda(R) (liraglutide 3 mg) (n=1,505) in combination with a reduced-calorie diet and increased physical activity resulted in significant improvements in cardiometabolic risk factors (such as blood pressure and cholesterol) compared with placebo (reduced-calorie diet and increased physical activity alone) (n=749).
At week 160, individuals treated with Saxenda(R) had lost more weight (6.1%) than those treated with placebo (1.9%) (estimated treatment difference [ETD] -4.3% [95% CI -4.9; -3.7], p